Heterogeneity of patients with high-intermediate and high-risk endometrial cancer included in prospective trials

Abstract

Objective: Adjuvant therapy for endometrial cancer remains controversial. Clinical and pathologic characteristics have been used to stratify women based on risk of recurrence. Recently, several prospective trials have examined the use of various combinations of adjuvant chemotherapy and radiation for women classified as high-intermediate and high risk. These trials included a wide spectrum of tumor types and stages. We assessed the long-term survival of women with high-intermediate and high-risk endometrial cancer as classified by GOG 249 and PORTEC-3.